BACKGROUND: By using proteomics and bioinformatics, we have previously identified a group of highly pancreas-specific proteins as candidate pancreatic ductal adenocarcinoma (PDAC) biomarkers. With the use of commercially available ELISAs, the performance of some of these candidates was initially evaluated in a relatively small serum cohort (n = 100 samples). This phase revealed that CUB and zona pellucida-like domains protein 1 (CUZD1) may represent a new, promising PDAC biomarker. METHODS: We performed detailed experiments to investigate the specificity of the commercial CUZD1 ELISA assay. CUZD1 was expressed in house in both bacteria and yeast expression systems. Recombinant CUZD1 and biological samples containing CUZD1, as well as commercial CUZD1 ELISA standards, were analyzed by Western blot, size exclusion HPLC, and mass spectrometry (LC-MS Orbitrap). RESULTS: We confirmed that instead of CUZD1, the commercial assay is recognizing a nonhomologous, known cancer antigen [cancer antigen 125 (CA125)]. CONCLUSIONS: We conclude that poor characterization of commercial ELISA assays is a factor that could lead to false biomarker discovery. To our knowledge, this is the first report documenting that a commercial ELISA marketed for one analyte (CUZD1) may, in fact, recognize a different, nonhomologous antigen (CA125).
BACKGROUND: By using proteomics and bioinformatics, we have previously identified a group of highly pancreas-specific proteins as candidate pancreatic ductal adenocarcinoma (PDAC) biomarkers. With the use of commercially available ELISAs, the performance of some of these candidates was initially evaluated in a relatively small serum cohort (n = 100 samples). This phase revealed that CUB and zona pellucida-like domains protein 1 (CUZD1) may represent a new, promising PDAC biomarker. METHODS: We performed detailed experiments to investigate the specificity of the commercial CUZD1 ELISA assay. CUZD1 was expressed in house in both bacteria and yeast expression systems. Recombinant CUZD1 and biological samples containing CUZD1, as well as commercial CUZD1 ELISA standards, were analyzed by Western blot, size exclusion HPLC, and mass spectrometry (LC-MS Orbitrap). RESULTS: We confirmed that instead of CUZD1, the commercial assay is recognizing a nonhomologous, known cancer antigen [cancer antigen 125 (CA125)]. CONCLUSIONS: We conclude that poor characterization of commercial ELISA assays is a factor that could lead to false biomarker discovery. To our knowledge, this is the first report documenting that a commercial ELISA marketed for one analyte (CUZD1) may, in fact, recognize a different, nonhomologous antigen (CA125).
Authors: Jungsun Kim; William R Bamlet; Ann L Oberg; Kari G Chaffee; Greg Donahue; Xing-Jun Cao; Suresh Chari; Benjamin A Garcia; Gloria M Petersen; Kenneth S Zaret Journal: Sci Transl Med Date: 2017-07-12 Impact factor: 17.956
Authors: Alison Chan; Ioannis Prassas; Apostolos Dimitromanolakis; Randall E Brand; Stefano Serra; Eleftherios P Diamandis; Ivan M Blasutig Journal: Clin Cancer Res Date: 2014-09-19 Impact factor: 12.531
Authors: Charles Garrigan; Jennifer Han; Pam Tolomeo; Katherine J Johnson; Stephen R Master; Ebbing Lautenbach; Irving Nachamkin Journal: Am J Transl Res Date: 2016-10-15 Impact factor: 4.060
Authors: Lisa Ehlers; Marieluise Kirchner; Philipp Mertins; Cindy Strehl; Frank Buttgereit; Timo Gaber Journal: Int J Mol Sci Date: 2022-05-02 Impact factor: 5.923